Dr. Christopher Missling's interview in Nov. 21, 2014, right before Anavex started its Phase 2 study of Anavex 2-73 on Altheimer's Disease.
The complete stock trend of AVXL thereafter (Nov. 2014 - Nov. 2015). Pay close attention to the abrupt fall after AVXL briefly reached the $14.84 peak. Many investors would get trapped there for a long time.
If you don't have the stomach for risk and stock volatility, DO NOT PLAY AVXL.
This is not investment advice. Your money your decision
